ERS International Congress, Madrid, 2019:highlights from the General Pneumology Assembly by Vanfleteren, Lowie E G W et al.
  
 University of Groningen
ERS International Congress, Madrid, 2019
Vanfleteren, Lowie E G W; Blervaque, Léo; Franssen, Frits M E; Daines, Luke; Kocks,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Vanfleteren, L. E. G. W., Blervaque, L., Franssen, F. M. E., Daines, L., Kocks, J. W. H., Honkoop, P. J., &
Poberezhets, V. (2020). ERS International Congress, Madrid, 2019: highlights from the General
Pneumology Assembly. ERJ Open Research, 6(1). https://doi.org/10.1183/23120541.00323-2019
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 19-05-2020
ERS International Congress, Madrid,
2019: highlights from the General
Pneumology Assembly
Lowie E.G.W. Vanfleteren 1, Léo Blervaque2, Frits M.E. Franssen 3,4,
Luke Daines 5, Janwillem W.H. Kocks6,7, Persijn J. Honkoop8,9 and
Vitalii Poberezhets10
Affiliations: 1COPD Center, Sahlgrenska University Hospital and Institute of Medicine, Gothenburg University,
Gothenburg, Sweden. 2PhyMedExp, INSERM, CNRS, Montpellier University, Montpellier, France. 3CIRO, Horn,
The Netherlands. 4Dept of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the
Netherlands. 5Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and
Informatics, The University of Edinburgh, Edinburgh, UK. 6General Practitioners Research Institute,
Groningen, The Netherlands. 7Observational and Pragmatic Research Institute, Singapore. 8Dept of Public
Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands. 9Dept of Biomedical
Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. 10Dept of Propedeutics of Internal
Medicine, National Pirogov Memorial Medical University, Vinnytsya, Ukraine.
Correspondence: Lowie E.G.W. Vanfleteren, COPD Center, Sahlgrenska University Hospital and Institute of
Medicine, Gothenburg University, Vita Stråket 12, Göteborg 413 45, Sweden. E-mail: lowie.vanfleteren@gu.se
ABSTRACT This article contains highlights and a selection of the scientific advances from the European
Respiratory Society’s General Pneumology Assembly that were presented at the 2019 European Respiratory
Society International Congress in Madrid, Spain. The most relevant topics from the different groups will
be discussed, covering a wide range of areas including rehabilitation and chronic care, general practice and
primary care and M-health and E-health. In this review, the newest research and actual data as well as
award-winning abstracts and highlight sessions will be discussed.
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The European Respiratory Society International Congress is the world’s largest scientific and educational
conference in the field of respiratory medicine. For the Madrid 2019 Congress, 4315 abstracts were
accepted for presentation. The General Pneumology Assembly of the European Respiratory Society is the
largest of the 14 assemblies. In total 317 abstracts were presented in 20 sessions related to this assembly
and the four groups of which it consists. It is impossible for any delegate to follow all scientific and
clinical advances and breakthroughs presented during this conference. This review aims to provide the
reader with an overview of a few of the most interesting presentations of each group, deemed noteworthy
by the authors of this manuscript.
Pulmonary rehabilitation and chronic care
Session: Best abstracts in pulmonary rehabilitation and chronic care
Work presented in this session covered various important issues in pulmonary rehabilitation (PR), ranging
from optimising and maintaining the effects of exercise training to behavioural changes.
Because exercise intolerance often goes hand-in-hand with hypoxaemia in patients with idiopathic
pulmonary fibrosis (IPF), devices allowing a higher oxygen flow are of interest. SCHNEEBERGER et al. [1]
compared a novel device for supplemental oxygen therapy (SOT), the Oxymizer (Drive DeVilbiss
Healthcare, Port Washington, NY, USA), to the conventional nasal cannula (CNC) in 26 IPF patients with
SOT indication. 22 patients completed two endurance shuttle walk tests using, in a randomised cross-over
design, both Oxymizer or CNC. The use of Oxymizer instead of CNC improved walking capacity and
oxygen saturation on pulse oximetry SpO2 and was associated with lower heart and breathing rate. Despite
these effects, a majority of patients (64%) still preferred the CNC for daily use. The authors concluded that
offering SOT through Oxymizer could provide clinically relevant benefits for IPF patients.
Additional prognostic information in chronic obstructive pulmonary disease (COPD) patients can be
provided with the assessment of functional and exercise capacity, but this assessment is difficult to
implement in care context. Thus, WALSH et al. [2] aimed to test the prognosis value of 4 m gait speed
(4MGS) in a cohort of 371 patients with COPD attending hospital outpatient clinics. In a multivariate
analysis, they compared the predictive values of 4MGS, Age, forced expiratory volume in 1 s (FEV1) and
Sex (GAFS) index to the Age Dyspnoea Obstruction (ADO) index and FEV1. GAFS was predictive of
3-year mortality with a better discrimination than the other indexes, with an area under the curve (AUC)
of 0.74. The model was also validated in an independent cohort of 472 patients attending community
COPD clinics. The AUC for this cohort was 0.74. The authors concluded that gait speed can provide
additional prognostic information than ADO or FEV1 alone in COPD patients, in a feasible manner.
DUARTE FREITAS et al. [3] conducted a randomised-controlled trial to investigate whether a behavioural
change intervention can improve asthma control through an increase of physical activity levels. Control
group and intervention group followed the same usual care intervention, with an addition of 8 weeks of
behavioural change intervention focused on goal-setting and feedback for the intervention group. The
intervention had significant beneficial effects compared to the control group on asthma clinical control,
health-related quality of life and physical activity levels. Because improvement in asthma clinical control
and physical activity levels were correlated, the authors suggested that beneficial effects of the behavioural
change intervention on asthma clinical control were mediated by the increase in physical activity levels.
A randomised double-blind, cross-over study conducted by BONNEVIE et al. [4] aimed to investigate
whether noninvasive high- and/or low-frequency lumbar transcutaneous electrical nerve stimulation (HF
or LF TENS) can improve endurance capacity of COPD patients, as previously shown with intrathecal
administration of fentanyl. To meet these objectives, 10 COPD patients performed in a randomised order
three constant workload exercises associated with three modalities of stimulation, a sham TENS, an LF
TENS at 4 Hz, or a HF TENS at 100 Hz. LF and HF TENS did not induce differential effects compared to
the sham condition on dyspnoea, lower limb fatigue and endurance capacity. However, muscle
oxygenation tended to be higher in both TENS conditions compare to sham, reflecting, according to the
authors, a modulation of the quadriceps muscle activity.
While muscle dysfunction is well described in COPD patients, evidence regarding temporal muscle mRNA
responses to both aerobic exercise training (AET) and training cessation (TC) are lacking. LATIMER et al. [5]
conducted a trial in 19 COPD patients and 10 healthy controls investigating mRNA response after 1, 4 and
8 weeks of AET and 4 weeks after TC. 94 mRNAs involved in the response to AET were quantified with
RT-qPCR from muscle biopsies performed at each time. The authors observed a lack of increase in peak
oxygen uptake (V′O2peak) following exercise training in COPD patients compared to healthy controls.
However, muscle mRNA levels were altered in a similar manner in COPD patients and healthy controls in
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response to AET and TC. The authors concluded that skeletal muscle mRNA responsiveness to AET was
not blunted and dissociated from the whole-body V′O2peak.
A survival advantage has been described before for COPD patients who completed PR. Extracting data
from the Office for National Statistics concerning Wales and England from Jan 2015 to Jan 2017, EVANS
et al. [6] aimed to identify whether the case-mix severity differences or the effects of PR themselves
explained this advantage. 7092 COPD patients were included. 58% of the patients completed PR and these
patients differed from the non-completer group on age, dyspnoea, comorbidity occurrence, walking
distance, home oxygen use, smoking status and hospital admission. The mortality rate was lower in the
completer group even with adjustment for the parameters described above. This study described a higher
cumulative mortality in patients who did not complete PR, (HR 1.42 (95% CI 1.20–1.67)), after
adjustment for confounding factors.
While the beneficial effects of PR in COPD patients are well described, little is known about strategies
allowing long-term maintenance of these benefits. BLERVAQUE et al. [7] assessed the efficiency of a
pragmatic maintenance programme in COPD patients, with a follow-up of 5 years. This programme
included weekly supervised exercise training sessions completed with discussion groups and health
education. 144 COPD patients were included. The significant benefit provided by the PR on 6-min walk
distance (6MWD) remain significant up to 48 months after the PR discharge in the COPD patients
involved in the maintenance program. In the same way, the benefits on dyspnoea (MRC scale) and quality
of life (VQ11 questionnaire) were maintained up to 5 years and 4 years respectively.
General Practice and Primary care
Session: Diagnosis and assessment of airway diseases in primary care
There was a wide range of primary care content at the 2019 ERS International Congress. The Primary
Care Day focused on infections, vaccinations, and case studies with excellent speakers on day-to-day
respiratory cases. Our highlights this year come from the primary care oral presentations on Sunday 29
September, showcasing research into the diagnosis and assessment of airway diseases.
IRINEO GONZÁLEZ et al. [8], explained that spirometry training in Mexico is optional, and rarely performed
in primary care. Addressing this, an education programme was delivered to 439 primary care clinicians.
Initial testing identified 33% of participants did not know how to perform spirometry, and 37% had no
equipment. The education programme demonstrated a great improvement in participant knowledge. A
second phase of training including certification of spirometry was delivered 10 months later; however, due
to high staff turnover, only 70 of the original participants attended. Future research will consider
condensing education and certification into one instalment and increasing spirometry availability.
In the Netherlands, spirometry is straightforward to achieve, but the quality compared to American
Thoracic Society (ATS)/European Respiratory Society (ERS) standards [9] is unclear. To investigate, VAN DE
HEI et al. [10], assessed usefulness and quality of spirometry from 149 primary care patients. 88% of
spirometry readings were considered “clinically useful” by clinicians (two pneumonologists, 15 GPs),
meaning they felt able to make a diagnosis from spirometry and available clinical data. However, when
compared to the ATS/ERS standards only 13% of readings met the full criteria. Furthermore, when
clinician diagnoses were compared, there was little agreement between the pulmonologists (kappa=0.38
(95% CI 0.27–0.50)), or between general practitioners and pulmonologists (versus pulmonologist 1
kappa=0.39 (95% CI 0.22–0.44); versus pulmonologist 2; kappa=0.44 (95% CI 0.32–0.55)). These data
suggest that meeting the ATS/ERS criteria was not necessary for clinicians to feel confident in making a
diagnosis, though agreement between pulmonologists and between pulmonologists and GPs was poor.
Even if spirometry quality is sufficient, demonstrating expiratory airflow limitation in asthma can be
difficult. Bronchial provocation can be useful in the diagnostic assessment of asthma [11] but is
traditionally performed in hospitals [12]. Therefore, BINS et al. [13], investigated the safety and usefulness
of community performed bronchial provocation in a Dutch primary care diagnostic centre. 998 patients
underwent histamine bronchial provocation with no adverse events. The authors concluded bronchial
provocation of adults in the community was safe and feasible, could reduce the number of referrals to
secondary care and that under- and over-diagnosis of asthma occurred if bronchial provocation was
not used.
Objective tests are also used to monitor asthma control. To monitor children, guidelines recommend
measuring lung function routinely and, in some circumstances, Fractional exhaled nitric oxide (FENO) [14, 15].
Spirometry and FENO are used regularly in hospitals but less commonly in primary care. To investigate the
value of spirometry and FENO for monitoring asthma in primary care children, LO et al. [16], trained staff
in 10 general practices to perform the tests in the UK. Of the 612 children recruited with “GP diagnosed
asthma” or “suspected asthma”, 575 achieved spirometry and 472 completed FENO. 46% of children with
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available FENO and spirometry reported good control (Asthma Control Test (ACT)/Children’s Asthma
Control Test (CACT) >19) but had at least one abnormality identified by objective tests. Interestingly, 49%
of the 191 reporting poor control (ACT/CACT ⩽19), had normal spirometry and FENO <35 ppb. These
data suggest that assessing asthma in primary care using symptoms, or objective tests in isolation will not
provide a full picture of the child.
Two studies considered how to optimise management of adults with COPD. Firstly, BARON et al. [17],
investigated asthmatic traits in 3532 individuals with pulmonologist-diagnosed COPD or asthma-COPD
overlap (ACO). Over 60% had at least one “asthma sign”. 7% had a history of asthma, 13% had reversibility
of ⩾12% and 16% had atopy. They concluded that asthma traits could help primary care clinicians
consider which individuals with COPD are most likely to benefit from inhaled corticosteroids [18].
Secondly, JORDAN et al. [19] presented a prediction model to identify COPD patients at risk of
hospitalisation. Age, COPD Assessment Test score, percentage of predicted FEV1, respiratory admissions in
the past year, BMI and diabetes were valuable predictors for an individual being admitted within 2 years.
The model performed well (c-statistic 0.75 (95% CI 0.72–0.79) and will be externally validated.
The final abstract investigated the value of the STOP-BANG questionnaire (SBQ) [20] in identifying
individuals with obstructive sleep apnoea (OSA). PLANA PES et al. [21], recruited 565 primary care adults
(30–70 years). 38% scored ⩾3 on the SBQ and underwent home polysomnography. Of these, 93% were
diagnosed with OSA. The team concluded an SBQ ⩾3 could be an adequate threshold to screen for OSA
in primary care.
Overall, the session highlighted the breadth of research topics and methods used to investigate clinical
questions arising from primary care. Learning from researchers across different countries helped address
shared goals and challenges arising from efforts to maximise the value of new and existing questionnaires,
models and tests to improve the diagnosis and management of respiratory disease.
M-health/E-health
Session: M-health/e-health poster discussion session
This year the ERS experienced the birth of the special interest Group on m-health/e-health, in the General
Pneumology Assembly. This new group actively invites respiratory researchers, scientists, patient
organisations, industry representatives, technicians and statisticians with experience in digital technologies
to become a part of this movement and to contribute with their specific knowledge. At the m-health/
e-health poster discussion session, we got a marvellous first glimpse of the future of respiratory medicine
and were provided with a selected sample of current initiatives.
Telemedicine
Telemedicine is a very promising field of medicine, especially for hospitals caring for rural areas, because it
provides a way to overcome travelling distances. Additionally, it allows for further communication and
checks that would not be convenient in a regular setting. During the session, DE LAS HERAS et al. presented
the results of a randomised controlled trial in patients with IPF comparing usual care to tele-rehabilitation
with a Virtual Autonomous Physiotherapist Agent (VAPA), on exercise capacity and quality of life [22].
They showed that tele-rehabilitation with VAPA is feasible for IPF and found a significant difference in
the 6MWD. VILARINHO et al. presented the results of the introduction of continuous telemonitoring in
home mechanical ventilation. In 8% of patients, they found a clinically relevant situation to act, which
could be solved with just a phone call in 87% of cases [23]. This telemedicine troubleshooting could
enhance the compliance of long-term therapy in home respiratory therapies.
Health apps
In recent years, taking into account the growing number of smartphone users, we have seen apps rapidly
taking on a central role in people’s lives. They can be used to promote self-management, follow up disease
outcomes, detect deterioration early and provide information on a variety of issues. At our session,
RIJSSENBEEK-NOUWENS et al. showed that quality of life and asthma control remained at a higher level in
asthma patients after pulmonary rehabilitation if they used an e-health support platform compared to
those who received usual care. Interestingly, this was particularly so for high engagers of the e-health
system, suggesting that this is an important parameter to measure [24]. PINHEIRO et al. [25] displayed a
beautifully created app for children, making use of gamification to increase adherence. Children had to
perform a forced expiratory manoeuvre that was registered by their smartphone’s microphone. This
resulted, if performed properly, in a dragon creating a huge fireball, which blew away a structure and
interestingly, if performed sub-optimally, in smaller fireballs. The use of the app meant children
performed spirometry unknowingly, and optimal performance was incentivised, in an intuitive and fun
way. PUIG SANCHEZ et al. [26] presented trial results comparing a newly developed stop smoking app to
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usual care. It included motivational texts upon request and mini-games, which patients could start when
they felt the need for a smoke. They showed significantly increased cessation rates, which was all the more
impressive considering most patients in the intervention group hardly used the app. A low uptake in app
usage was a common feature across different presentations. Future research should focus on user
engagement from the start, for example by incorporating end-users in the design phase of the app.
Devices
The stethoscope is one of the defining features of the doctor, featuring prominently around the neck in
movies or television series that include doctor. But what if this stethoscope doesn’t actually need the
doctor any more? This is the central question that GRZYWALSKI et al. [27] sought to answer by assessing
multiple respiratory sounds with plug-in stethoscopes with automatic sound detection and analysis. This
automated device was significantly better at detecting different respiratory sounds than doctors.
Fortunately, health professionals are still required to interpret the plug-in stethoscope in the context of
medical history and other tests. However, it does paint a future whereby the actual presence of the patient
inside the hospital might no longer be required for all diagnostics. Another important area of innovation
is the emergence of “Quantified Self” and the use of all sorts of wearable devices. MANNÉE et al. [28]
presented the first model of an easy to use smart shirt, specifically designed to assess tidal volumes during
different types of daily activity. This could be used at home instead of having to come to the clinic for
exercise testing.
Artificial intelligence and big data
Artificial intelligence (AI) and machine learning techniques are of great interest for many involved in
m-health. Of course, this presents a very promising new field of medicine, with hopeful reports of earlier
detection and more personalised treatment of all sorts of diseases. DEMCHUK et al. [29] showed an
automated decision support system providing personalised treatment advice for pneumonia, taking into
account all comorbidities and interactions with other medication. This resulted in significantly fewer
medication errors. However, the use of AI in medicine is certainly not a field without controversy.
AI provokes interest as it is potentially superior to existing methods of analysis but also uncertainty as data
analysis by neural networking is not well understood. This poses the question: “Should we follow the advice
of a system if we do not understand how the system came to that advice?” Interestingly, DAS et al. [30]
presented a new type of pulmonary function interpretation algorithm that shed some light on which
determinants played a role in AI decision making and provided a new score that gives an indication of
whether AI is right or not. Hopefully, with further development, we can get more of a grip on how to use
AI in the future and understand it better.
The ERS Congress 2019 was of great interest for those engaged in digital medicine. As well as
presentations, the new m-health/e-health Group had its first meeting and shared ideas for next year’s
conference, to present in the digital health sessions.
Concluding remarks
The authors of this article hope that this short summary of the impressive amount of lung research and
advances in pulmonary care presented through the General Pneumology Assembly of the ERS creates
curiosity to follow up on topics of interest to each individual reader.
It was our goal to stimulate discussion and exchange of scientific novelties and clinical developments. We
also hope to have encouraged the readership to attend the ERS International Congress 2020 in Vienna.
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